|Bid||52.36 x 0|
|Ask||52.40 x 0|
|Day's Range||52.32 - 53.39|
|52 Week Range||31.81 - 76.68|
|Beta (3Y Monthly)||5.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.00|
The CEOs of the leading marijuana companies have their eyes set on two states to follow Illinois in legalizing recreational marijuana.
Cannabis stocks were mostly lower on Tuesday, as the broader markets faltered and investors awaited the next key catalysts for the sector.
Canopy bought at least a dozen smaller cannabis producers over the past year, but the string of acquisitions has come to an end, Linton told the publication. Flush with billions of dollars from Constellation Brands, Inc. (NYSE: STZ)'s investment, the cannabis company is now "more interested in what exists in the pharmaceutical world," he said. Need more cannabis news?
Canopy Growth stock took a tumble after the Canadian company reported sluggish marijuana sales. Canopy CEO Bruce Linton said in an interview that “massive” margins are coming.
On June 24, Cormark Securities cut Canopy Growth's (WEED) (CGC) price target to 65 Canadian dollars from 70 Canadian dollars after the company released its earnings, which largely missed expectations. Cormark maintained its "buy" recommendation on the stock, which was in line with the consensus of the 20 analysts covering the stock.
Canopy Growth (WEED) (CGC) has a strong balance sheet with a cash balance of ~4.5 billion Canadian dollars, which it received from an infusion from Constellation Brands.
Marijuana stocks have been a volatile but largely outperforming group in 2019. But an analyst warns that while some companies are living up to the hype, others have risen too far, too fast.
EBITDA is a measure of core performance that tells us about how a company has done in terms of profitability before any effects of charges such as depreciation (noncash charge) and the impact of interest and tax (cash charges).
Canopy Growth and Cronos Group expressed reservations about Canada's THC limits on cannabis-infused edibles and beverages. Most marijuana stocks rose.
After Canopy Growth's (WEED) (CGC) release of its fiscal 2019 fourth-quarter earnings results, its price took an 8% dive as its stock went into correction mode. Naturally, this change had an impact on its valuation.
During its earnings call on June 21, Canopy Growth (WEED) (CGC) discussed its ongoing merger and acquisition activities. The company's massive backing of 5 billion Canadian dollars from Constellation Brands (STZ) has provided it with the much-needed resources to build out its growth ambition.
Several Wall Street analysts have come out bullish on cannabis stocks in recent months, but one analyst said Monday that Aurora Cannabis Inc (NYSE: ACB ) is the clear top choice in the sector. The Analyst ...
Powered by a deal with Corona-maker Constellation Brands Inc that has left it with $4.5 billion to invest, Canopy is in pole position to cash in on Canada's legalization of marijuana for recreational use as well as expectations that the United States may follow. Constellation is betting in part on the promise that federal legislation might eventually follow moves by state governments in the United States to legalize, opening the door to legal production countrywide, and there have been tentative signs that others may follow.
After Canopy Growth's (WEED) (CGC) fiscal 2019 fourth-quarter earnings release, its consensus price target trended lower as analysts adjusted their expectations on the back of its earnings results.
has a five-year track record of solid revenue growth, improved margins, and strong profitability. More recently, though, the stock is getting pulled into the ongoing trade war between the United States and China. Earnings per share increased 51% in fiscal 2018 (May) to $16.79 per diluted share.
Canopy Growth (WEED) (CGC) held its fiscal 2019 fourth-quarter earnings call on June 21. During the call, it provided critical updates about its near-term performance and growth initiatives. The company's margins took a hit during its most recent quarter. Let's look at what its management had to say.
Canopy Growth Corporation (NYSE: CGC) is adding to its production capacity, announcing Monday that it received a license for an outdoor cultivation site in Northern Saskatchewan. Canopy is projecting revenue generation from the rollout of the second phase of Canadian marijuana products in October. Canopy said it has several IP-protected pieces of equipment and processes to go along with its patents on vape production and extraction.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
Canopy Growth (WEED) (CGC), which reported its fiscal 2019 fourth-quarter earnings results on June 20, largely disappointed the market, which led to a sell-off in its stock on June 21, when it fell nearly 7.6%.
Friday was a difficult day for cannabis companies after Canopy Growth Corp (NYSE: CGC )'s earnings report showed a quarter-over-quarter decline in Canadian recreational usage, CNBC's Jim Cramer said during ...